Home Newsletter Honored Guests Blog About Us Work With Us Sponsor & Advertise Be a Guest The Production Suite Get the Briefing
Skip to main content

Open Door Salon

Ryan Cawood

Ryan Cawood

Co-Founder & CEO, Lab Thread

Ryan Cawood, PhD, is Co-Founder and CEO of Lab Thread, where he works on the data layer underneath laboratory science. He came up through the bench and stayed close to it. After completing his PhD he founded his first business, developing materials that moved into GMP environments and out to contract manufacturers serving other companies.

At Lab Thread the question he works on is where AI earns its place in laboratory workflows. His focus sits on the unglamorous problem underneath every AI promise in life sciences: if the underlying data is fragmented, undocumented or wrong, the confident answer at the end is worth nothing. On Open Door Salon he sets out where an AI error actually enters a preclinical program, and why the most expensive version of it does not surface for months.

Frequently Asked Questions About Ryan Cawood

Who is Ryan Cawood?

Ryan Cawood, PhD, is Co-Founder and CEO of Lab Thread, where he works on the data layer underneath laboratory science. He came up through the bench and has stayed close to it. After completing his PhD he founded his first business, developing materials that moved into GMP environments and out to contract manufacturers serving other companies.

What does Ryan Cawood work on at Lab Thread?

Ryan Cawood is Co-Founder and CEO of Lab Thread, where he works on the data layer underneath laboratory science, and the question he takes up there is where AI earns its place in laboratory workflows. His focus is the unglamorous problem underneath every AI promise in life sciences: if the underlying data is fragmented, undocumented or wrong, the confident answer at the end is worth nothing.

What does Ryan Cawood argue about AI in the lab?

Ryan Cawood treats a model as something to be checked. On Open Door Salon he said of AI tools that “it really does need to be treated like a colleague. You wouldn’t trust everything that a colleague told you as gospel all the time”. On who owns an AI-assisted submission, he pointed to the FDA position: “the FDA has been very clear that a company that submits data to the FDA is 100% legally responsible for that data regardless of where it comes from”.

What example does Ryan Cawood give of a costly AI error in the lab?

Ryan Cawood sets out on Open Door Salon where an AI error actually enters a preclinical program, and why the most expensive version of it does not surface for months. His example of the delayed kind is a cell line: “the cell line you’ve spent 9 months making is now no longer viable in a GMP environment”.

What does Ryan Cawood say about the cost of AI tools?

Ryan Cawood, Co-Founder and CEO of Lab Thread, describes a deferred cost under every AI subscription. On Open Door Salon he put it this way: “these companies are actually underwriting the cost of service serving you the AI result to the degree of 90%”.

On Open Door Salon

“Ryan Cawood and Raphaël Ognar on What Happens When AI Gets Drug Discovery Wrong”
Ryan Cawood & Raphaël Ognar · August 26, 2026

Episode page & show notes on Open Door Salon

“the FDA has been very clear that a company that submits data to the FDA is 100% legally responsible for that data regardless of where it comes from”Ryan Cawood, on Open Door Salon (on who owns an AI-assisted submission)
“the cell line you’ve spent 9 months making is now no longer viable in a GMP environment”Ryan Cawood, on Open Door Salon (on why the costly AI error is a delayed one)
“it really does need to be treated like a colleague. You wouldn’t trust everything that a colleague told you as gospel all the time”Ryan Cawood, on Open Door Salon (on how to use a model responsibly)
“these companies are actually underwriting the cost of service serving you the AI result to the degree of 90%”Ryan Cawood, on Open Door Salon (on the deferred cost under every AI subscription)

In this episode

  • The publication that did not exist
  • The AI admitted it invented the publication
  • The DNA sequence it read confidently and wrong
  • Who is liable when the model is wrong
  • What a mistake actually looks like in a lab
  • Build checkpoints into the prompt, not just at the end
  • Failure at big pharma versus failure at a small biotech
  • Trials are designed for approval, not for the real world
  • Nine months of chain of custody, recorded on paper
  • Greed versus outcome in the AI bubble
  • The pitch deck with no mention of AI

Topics

AI in Drug DiscoveryLaboratory Data IntegrityGMP and Chain of CustodyCell Line DevelopmentBiotech Software

Watch on Open Door Salon

What Happens When AI Gets Drug Discovery Wrong | Ryan Cawood & Raphaël Ognar

Open Door Salon brings life-sciences leaders into candid conversation. Every Monday, the week's takeaways land in your inbox.

Subscribe on Substack →
The Briefing

Need the life-sciences signal but short on time?

Get the free quarterly briefing: every guest from the quarter, in one sitting. What decides whether a therapy reaches a patient, gets funded, and can be trusted.